Endostatin's antiangiogenic signaling network

被引:362
|
作者
Abdollahi, A
Hahnfeldt, P
Maercker, C
Gröne, HJ
Debus, J
Ansorge, W
Folkman, J
Hlatky, L
Huber, PE
机构
[1] Univ Heidelberg, Sch Med, Dept Radiat Oncol, German Canc Res Ctr, Heidelberg, Germany
[2] Univ Heidelberg, Sch Med, Dept Radiat Oncol, Heidelberg, Germany
[3] Harvard Univ, Sch Med, Dept Radiat Oncol, Dana Farber Canc Inst, Boston, MA USA
[4] German Genome Resource Ctr, Berlin, Germany
[5] German Canc Res Ctr, Dept Mol Pathol, D-6900 Heidelberg, Germany
[6] European Mol Biol Lab, Heidelberg, Germany
[7] Harvard Univ, Sch Med, Surg Res Lab, Dept Surg,Childrens Hosp, Boston, MA 02115 USA
[8] Harvard Univ, Sch Med, Dept Surg, Boston, MA 02115 USA
[9] Harvard Univ, Sch Med, Dept Cell Biol, Boston, MA 02115 USA
关键词
D O I
10.1016/S1097-2765(04)00102-9
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
It is here demonstrated that the set of gene expressions underlying the angiogenic balance in tissues can be molecularly reset en masse by a single protein. Using genome-wide expression profiling, coupled with RT-PCR and phosphorylation analysis, we show that the endogenous angiogenesis inhibitor endostatin down-regulates many signaling pathways in human microvascular endothelium associated with proangiogenic activity. Simultaneously, endostatin is found to upregulate many antiangiogenic genes. The result is a unique alignment between the direction of gene regulation and angiogenic status. Profiling further reveals the regulation of genes not heretofore associated with angiogenesis. Our analysis of coregulated genes shows complex interpathway communications in an intricate signaling network that both recapitulates and extends on current understanding of the angiogenic process. More generally, insights into the nature of genetic networking from the cell biologic and therapeutic perspectives are revealed.
引用
收藏
页码:649 / 663
页数:15
相关论文
共 50 条
  • [1] Endostatin's endpoints-deciphering the endostatin antiangiogenic pathway
    Benezra, R
    Rafii, S
    CANCER CELL, 2004, 5 (03) : 205 - 206
  • [2] Endostatin: The logic of antiangiogenic therapy
    Abdollahi, A
    Hlatky, L
    Huber, PE
    DRUG RESISTANCE UPDATES, 2005, 8 (1-2) : 59 - 74
  • [3] The antiangiogenic and therapeutic implications of endostatin
    Ren, B
    Höti, N
    Rabasseda, X
    Wang, YZ
    Wu, M
    METHODS AND FINDINGS IN EXPERIMENTAL AND CLINICAL PHARMACOLOGY, 2003, 25 (03): : 215 - 224
  • [4] Antiangiogenic treatment of AML with endostatin.
    Schuch, G
    Erguen, S
    Gehling, U
    Hossfeld, DK
    Fiedler, W
    BLOOD, 2003, 102 (11) : 872A - 873A
  • [5] Endostatin: a promising drug for antiangiogenic therapy
    Cirri, L
    Donnini, S
    Morbidelli, L
    Chiarugi, P
    Ziche, M
    Ledda, F
    INTERNATIONAL JOURNAL OF BIOLOGICAL MARKERS, 1999, 14 (04): : 263 - 267
  • [6] The antiangiogenic molecule endostatin inhibits trophoblast invasion
    Pollheimer, J
    Husslein, P
    Knöfler, M
    PLACENTA, 2004, 25 (8-9) : A14 - A14
  • [7] Endostatin imaging to help understanding of antiangiogenic drugs
    Barthel, H
    LANCET ONCOLOGY, 2002, 3 (09): : 520 - 520
  • [8] Antiangiogenic effects of recombinant human endostatin in lung cancers
    He, Lang
    Zhao, Chaofen
    Li, Yunxiang
    Du, Guocheng
    Liu, Kang
    Cui, Dandan
    Tang, Lina
    Wu, Xun
    Wen, Shimin
    Chen, Hong
    MOLECULAR MEDICINE REPORTS, 2018, 17 (01) : 79 - 86
  • [9] Possible role of endostatin in the antiangiogenic therapy of diabetic retinopathy
    Behl, Tapan
    Kotwani, Anita
    LIFE SCIENCES, 2015, 135 : 131 - 137
  • [10] E-selectin is required for the antiangiogenic activity of endostatin
    Milstone, DS
    Yu, Y
    Moulton, K
    Hoye, E
    Davis, VM
    Bischoff, J
    FASEB JOURNAL, 2002, 16 (04): : A215 - A215